





Sustainable Competence in Advancing Healthcare

TRAINING COURSE ON SAFETY IN BRACHYTHERAPY

14-18 November 2016 Vienna, Austria

SAFETY INITIATIVES

FROM A MANUFACTURING STANDPOINT

Eise Jan Kromhout van der Meer Representing COCIR Senior Product Specialist ELEKTA Ali Halici
Representing COCIR
Manager Service Engineering & Documentation ELEKTA



SAFETY ASPECTS

Improving safety further through:

- Continuous product improvement
- Better integrated solutions (TPS, OIS, RAL) to further avoid use errors
- Advance Dicom standards for brachytherapy
- Innovation: integrate therapy with live imaging and dose measurement, dose evaluation/summation
- More focus on QA aspects (tools, software)
- Prepare for future regulations and standards






RISKS AND BENEFIT ANALYSIS

- With the new Medical Device Regulation becoming effective in 2017, there is more focus on riskbenefit analysis and clinical evaluation
- COCIR is actively involved in discussions with the European Comission regarding the impact of this and other regulations on radiotherapy









PMS - CAPA

Requirements

Human
Factor
Analysis

PMCF

Clinical Investigation MDR art 2.15(e)

'benefit-risk determination'
means the integration of all
assessments of benefit and
risk of possible relevance for
the use of the device for the
intended purpose, when used
in accordance with the
intended purpose given by
the manufacturer;

Harmonized Standards (CS)

Risk Management

Risks

Benefits


Benefits outweigh the risks

Clinical Evaluation


Vali-dation
/
Simulated
Use

Verification















(GPRS 1, 2, 5 / ISO 14971 / ISO 62366)

Reduce foreseeable risk, use error and undesirable side-effects as far as possible & meet State of the Art:

- by safe design and manufacture
- 2. protection measures, including alarms
- provide information for safety (warnings/precautions/con traindications) and training to users.


Evaluate effectiveness of **risk control** measures.

Assure risk control **traceability**.









Vitamin D:

- * Reduces Risk of Cancer
- * Lowers Inflammation
- * Boosts Immune Function *Prevents Bone Loss
- * Regulates 2,00+ Genes
- * Reverses Depression

- *Lowers Blood Pressure
- *Optimizes Body Weight
- *Helps with MS and **Autism**







Requirements

> Human Factor Analysis



PMCF

Benefits/ Risks **Determin** ation

Harmonized Standards (CS)



Acceptable Risk

Investigation

Clinical

Vitamin D:

- * Reduces Risk of Cancer
- *Lowers Blood Pressure * Lowers Inflammation *Optimizes Body Weight
- * Boosts Immune Function *Prevents Bone Loss
- * Regulates 2,00+ Genes
- * Reverses Depression

*Helps with MS and Autism

CE: Benefits

PMS -

CAPA

Vali-dation Simulated Use

Verification





CONTROL OF SOURCE LOGISTICS



- Transportation of radioactive material is heavily regulated and has to comply with IAEA standards, Hass directive, IATA regulations, etc.
- Storage and security procedures at the hospital are less consistently regulated, as are licenses, e.g. activity limits
- Further improve source logistics, turnaround time
- Secure source supply and manufacturing (reactor)






GROW BRACHYTHERAPY

- Promote brachytherapy to the medical profession and patients for its efficacy, accuracy, minimal side effects, efficiency
- Promote brachytherapy to ministries, health insurance agencies, buying groups as a healthy investment
- Ensure continuity (source delivery, equipment, support, consumables) by adherence to quality standards and regulations

This is only possible when manufacturers, regulators and users work together to keep brachytherapy safe and make it even safer!











Sustainable Competence in Advancing Healthcare

THANK YOU FOR YOUR ATTENTION